• Article highlight
  • Article tables
  • Article images

Article Metrics




Downlaod Files

   


Article Access statistics

Viewed: 263

PDF Downloaded: 245

Raja C, Sudhakar T, Jambukeswaran PST, Ugeneshwaran M, and Manivannan: PRP in acromio-clavicular joint arthritis – A prospective analysis


Introduction

Acromioclavicular joint (ACJ) is regarded as a “forgotten joint”.1, 2 Though the emphasis has always been on the much larger glenohumeral joint, the acromioclavicular joint pathologies are one of the common causes of shoulder pain.3 The most common of these is the acromioclavicular joint arthritis.4 This can be primary or secondary to trauma or sepsis. The diagnosis is crucial. The patient presents with anterior or superior shoulder pain. Glenohumeral joint pathologies like cuff tear, instability, arthritis, and impingement syndrome should be ruled out.

The management can be conservative or surgical.5 There is a lacuna in the literature regarding the exact protocol for their management. Surgery is generally advised if the symptoms do not improve after a trial of conservative management for a period of more than six months.6 The conservative measures include activity modification, physiotherapy, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), and Intra-articular Steroid Injections (ISI). ISI has been used with variable success rates and the long-term effects are doubtful.7

With the advent of Platelet Rich Plasma (PRP), it has been tried in various inflammatory conditions and tendinopathies with promising results.8 The results of intra-articular injection of PRP in osteoarthritis of knee and hip have also proven to be useful.9 In this study, we have evaluated the results of PRP in ACJ arthritis in patients who failed to respond to exercise and NSAIDs.

Materials and Methods

A diagnosis of ACJ arthritis was made based on the clinical and radiological features. A patient with shoulder pain in whom the cuff pathology, instability, and impingement were ruled out, with clinical features of ACJ arthritis, like tenderness on ACJ, positive scarf sign (positive passive adduction compression test), painful abduction beyond 140 degrees, and restricted internal rotation was radiographically evaluated. When there is radiographic correlation, a diagnosis of ACJ arthritis was made. The patients were started on physiotherapy and NSAIDs. Those patients that were not responding for 2 months on this treatment or those that were worsening were counseled for PRP injection. Patients who were willing were enrolled in the study. Patients with pre-existing other shoulder pathologies, those less than 18 years old, and those with inflammatory arthritis were excluded from the study.

The PRP was prepared by manual double spin method according to the institute’s protocols. 20 mL of venous blood with sodium citrate was centrifuged at 1000 RPM for 10 minutes followed by 1500 RPM for 10 minutes. 1 mL of PRP was then injected into the ACJ under aseptic precautions.

Patients were evaluated at follow-up using the Constant score at follow up. Statistical analysis was performed using SPSS (IBM version 25). Paired data were analyzed using the paired t-test.

Results

14 patients including 17 shoulders were included in the study of which one patient lost to follow up. The remaining 13 patients including 16 shoulders were followed up for an average of 8 months (6 to 14 months). The average age at the time of injection was 51 years (range: 32-63 years). 3 patients had bilateral ACJ involvement. 4 had left ACJ involvement and the rest had right side involvement. 8 were male patients and 5 were females. All patients had primary ACJ arthritis. The mean pre-injection constant score was 45 (range 28-70). The mean score at the end of 1 month follow up was 69 (range 56-89). At the end of 3 months, the mean score was 81 range (63-93). Both were statistically significant improvements when compared with each other and to the pre-injection score (P=0.003,0.0021,0.04 respectively). At the end of 6 months, the score was 89 range (58–94). This sequential improvement was not however statistically significant.

Figure 1

Comparison of Constant scores of 16 shoulders pre and post-injection

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/9ba512f1-ece2-4ffa-8ed6-b8a60067c42eimage1.png

Discussion

Arthritis of the ACJ is the common cause of ACJ pain. It results because of the repeated strain at the joint particularly in persons with repeated overhead use of the shoulder involving lifting activities. There are degenerative and osteolytic changes in the distal clavicle.10 The management involves a conservative trial followed by arthroscopic or open distal clavicular resection in cases with persistent symptoms.5

PRP has been the discovery of the last decade in musculoskeletal medicine.11, 12 It’s supposed effectiveness, apparent lack of side effects, autologous nature, low cost, and promising scope has made us try it for various chronic conditions. Starting with tendinopathies it has been tried in managing wound complications and as a means of postponing surgery in degenerative conditions like osteoarthritis of knee.13, 14, 15

PRP is a cocktail with supraphysiological levels of platelets.16 These when activated release a high concentration of various growth factors including but not limited to basic fibroblast growth factor, transforming growth factor, vascular endothelial growth factor, platelet-derived growth factor, and epidermal growth factor among others. These growth factors are purported to have a supra-physiological healing effect on the tissues that they come in contact with. The exact mechanism of such an effect and the exact concentration of growth factors needed are still not clear. Generally, researchers agree that the platelet concentration of five to six times the normal is required.17 The rationale of the use of PRP in osteoarthritis has been its chondroprotective and regenerative effect.18 Activated platelets suppress the release of nuclear factor K beta from the chondrocytes halting the disease progress. PRP has shown promising results in osteoarthritis of the knee and hip. This with the excellent safety profile enabled us to try it in ACJ arthritis.

Researchers have suggested a three to six sittings PRP regimen for osteoarthritis of the knee.19 We had used a single injection of PRP in ACJ arthritis patients. We used the manual double spin method. Method of preparation and the resulting platelet concentration has been attributed to variable results while using PRP. There are several commercially available kits for PRP preparation. However, studies have shown equivalent efficacy between commercially available kits and manual double spin method.20

The results of our pilot study show that PRP can reduce pain and improve the shoulder function rapidly which is at the least maintained for six months. We noticed no significant complications in the study. ISI in ACJ arthritis has not been always reliable. PRP use seems to be more biological. ISI always comes with the slight risk of increased infection rates in future surgeries. These make PRP more ideal than ISI for the treatment of any degenerative arthritis including ACJ arthritis.

Our study is a pilot study with short term follow up. There was no control arm. Future randomized control trials comparing the efficacy of PRP and ISI are needed the establish the superior treatment method.

Conclusion

ACJ arthritis is one of the common causes of shoulder pain. In our pilot study, PRP has been a promising option to treat primary ACJ arthritis. Future RCTs are needed to establish it as a superior option in the management of ACJ arthritis.

Conflict of Interests

All authors have declared no conflict of interests.

Conflict of Interest

None.

References

1 

J Waxman Acromioclavicular disease in rheumatologic practice--the forgotten jointJ La State Med Soc Off Organ La State Med Soc1977129113

2 

C Krestan B Pretterklieber M Pretterklieber J Kramer Acromioclavicular joint : The “forgotten” jointRadiol201959325772

3 

P Zanca Shoulder pain: involvement of the acromioclavicular joint. (Analysis of 1,000 cases).Am J Roentgenol Radium Ther Nucl Med1971112349350610.2214/ajr.112.3.493

4 

A. J. K. Östör C. A. Richards A. T. Prevost C. A. Speed B. L. Hazleman Diagnosis and relation to general health of shoulder disorders presenting to primary careRheumatol2005446800510.1093/rheumatology/keh598

5 

S Docimo D Kornitsky B Futterman DE Elkowitz Surgical treatment for acromioclavicular joint osteoarthritis: patient selection, surgical options, complications, and outcomeCurr Rev Musculoskeletal Med2008121546010.1007/s12178-008-9024-5

6 

G Farrell L Watson H Devan Current evidence for nonpharmacological interventions and criteria for surgical management of persistent acromioclavicular joint osteoarthritis: A systematic reviewShoulder Elb201911639541010.1177/1758573219840673

7 

S Hossain C Ayekoloye O Odumala L Jacobs Intraarticular steroid injection in the treatment of primary acromioclavicular arthritis. an assessment of therapeutic effectivenessOrthop Proc2003857210.1302/0301-620X.85BSUPP_I.0850072c

8 

M Cruciani M Franchini C Mengoli Platelet-rich plasma for sports-related muscle, tendon and ligament injuries: an umbrella reviewBlood Transfus Trasfus Sangue201917646578

9 

I Andia N Maffulli Platelet-rich plasma for managing pain and inflammation in osteoarthritisNat Rev Rheumatol20139127213010.1038/nrrheum.2013.141

10 

NA Mall E Foley P N Chalmers BJ Cole AA Romeo BR Bach Degenerative Joint Disease of the Acromioclavicular JointAm J Sports Med2013411126849210.1177/0363546513485359

11 

P. Kumar Gupta A. Acharya V. Khanna S. Roy K. Khillan S. Nathan Sambandam PRP versus steroids in a deadlock for efficacy: long-term stability versus short-term intensity—results from a randomised trialMusculoskelet Surg202010432859410.1007/s12306-019-00619-w

12 

RS Dhillon EM Schwarz MD Maloney Platelet-rich plasma therapy - future or trend?Arthritis Res Ther201214421910.1186/ar3914

13 

H Badsha G Harifi WD Murrell Platelet Rich Plasma for Treatment of Rheumatoid Arthritis: Case Series and Review of LiteratureCase Rep Rheumatol20201710.1155/2020/8761485

14 

X Chen IA Jones C Park CT Vangsness The Efficacy of Platelet-Rich Plasma on Tendon and Ligament Healing: A Systematic Review and Meta-analysis With Bias AssessmentAm J Sports Med201846820203210.1177/0363546517743746

15 

H Johal M Khan SHP Yung MS Dhillon FH Fu A Bedi Impact of Platelet-Rich Plasma Use on Pain in Orthopaedic Surgery: A Systematic Review and Meta-analysisSports Health20191143556610.1177/1941738119834972

16 

T E Foster B L Puskas B R Mandelbaum M B Gerhardt S A Rodeo Platelet-rich plasma: from basic science to clinical applicationsAm J Sports Med20093711225972

17 

J De La Mata Plasma rico en plaquetas: ¿un nuevo tratamiento para el reumatólogo? Reumatol Clín2013916671

18 

GM van Buul W L.M. Koevoet N Kops PK Bos JAN Verhaar H Weinans Platelet-Rich Plasma Releasate Inhibits Inflammatory Processes in Osteoarthritic ChondrocytesAm J Sports Med2011391123627010.1177/0363546511419278

19 

M Kenmochi Clinical outcomes following injections of leukocyte-rich platelet-rich plasma in osteoarthritis patientsJ Orthop202018143910.1016/j.jor.2019.11.041

20 

R Dhurat MS Sukesh Principles and methods of preparation of platelet-rich plasma: A review and author′s perspectiveJ Cutan Aesthet Surg2014741899710.4103/0974-2077.150734



jats-html.xsl

© This is an open access article distributed under the terms of the Creative Commons Attribution License - Attribution 4.0 International (CC BY 4.0). which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.